- Company
- Novartis starts reimbursement discussions for Zolgensma
- by Eo, Yun-Ho Aug 20, 2021 05:56am
- After ‘Kymriah,’ Novartis has now begun the reimbursement listing process for ‘Zolgensma.' According to industry sources, the application for the reimbursement of Novartis Korea’s Zolgensma (onasemnogene abeparvovec-xioi) that was submitted through the approval-benefit appraisal linkage system will be put on the agenda for deliberatio
- Policy
- The current health insurance premium increase rate is 2.91%
- by Lee, Hye-Kyung Aug 20, 2021 05:56am
- Health authorities have refuted allegations that health insurance premiums have been raised for the success of health insurance policies. The MOHW and the NHIS recently released a statement by the Korea Enterprises Federation (KEF) explaining that "reorganization, including a cap on health insurance premiums, is a reasonable and fair resul
- Policy
- Seven companies are supplying flu vaccines this year
- by Lee, Tak-Sun Aug 20, 2021 05:55am
- SK Bioscience will focus on COVID vaccine after consulting with the KDCA. The market share of the GC Pharma is likely to increase. Two imported vaccines including Sanofi and GSK Flu vaccines, which will be distributed and sold in Korea this year, are nine items from seven companies, down three from the previous year. SK Bioscience, which had
- Policy
- Hanmi's Suvast 2.5mg has been approved
- by Lee, Tak-Sun Aug 19, 2021 06:03am
- There was no Rosuvastatin 2.5 mg available.Hanmi has started to create a new market by pushing for the approval of combination drug. The MFDS approved Hanmi's Suvast 2.5mg on the 17th. It is Rosuvastatin 2.5mg, which is not released in Korea. It is used in primary hypercholesterol and complex hyperlipidemia. Ministry of Health, Labour and
- Policy
- PPIs benefit from ranitidine’s market removal
- by Lee, Jeong-Hwan Aug 19, 2021 06:03am
- With proton pump inhibitors (PPI) enjoying reflective interest in sales from the market removal of ranitidine, which was banned due to detection of the potentially carcinogenic substance NDMA(N-Nitrosodimethylamine), criticism is rising that national health insurance finances are being unnecessarily wasted. The point is that PPIs cost on
- Company
- The Supreme Court again rejected α-GPC suspension
- by Chon, Seung-Hyun Aug 19, 2021 06:02am
- The Supreme Court again rejected α-GPC suspension to negotiate the withdrawal of Choline alfoscerate. Pharmaceutical companies finally lost the withdrawal negotiations. According to an industry on the 17th, the Supreme Court's special department 2 decided to reject discontinuance of trials in negotiations on the recovery of the Choline al
- Policy
- It plans to expand its supply of Moderna vaccines in Aug/Sep
- by Kim, Jung-Ju Aug 19, 2021 06:02am
- It plans to expand its supply of Moderna vaccines in August and September. Samsung Biologics' distribution in Korea is still pending. A government delegation to the U.S. announced the results after visiting Moderna The government received an apology from Moderna for the disruption in the domestic supply of COVID vaccines and announced tha
- Company
- Will AML drug Xospata be reimbursed through PE exemption?
- by Eo, Yun-Ho Aug 18, 2021 05:52am
- Whether the new leukemia drug Xospata that is attempting reimbursement through the PE exemption track will be able to be listed for insurance benefit in Korea is receiving attention. According to industry sources, Astellas Korea’s acute myeloid leukemia (AML) treatment Xospata (gilteritinib), which applied for reimbursement through the P
- Company
- Hanmi & Organon maintain ₩70 billion worth contract
- by Kim, Jin-Gu Aug 18, 2021 05:52am
- Hanmi has maintained a copromotion contract with Organon, which is separated from MSD. According to the Financial Supervisory Service on the 18th, Hanmi signed a domestic copromotion contract with Organon in the second quarter. The contract is due at the end of this year. The items include hair loss treatment Propecia, prostate hypertroph
- Policy
- Indication extensions filed by Abilify generics increase
- by Lee, Tak-Sun Aug 18, 2021 05:51am
- After Yungjin Pharm finally succeeded in invalidating the use patent of Abilify (aripiprazole·Korea Otsuka Pharmaceutical) after 6 years of patent dispute, other generics products of Abilify are now seeking to extend its indications. The use patent that was in dispute had protected Abilify’s ‘bipolar disorder’ indication, due to which
